

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 2, 2000
 FULBRIGHT & JAWORSKI L.L.P.

By


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : JAGER, et al.
 Serial No. : 09/451,739
 Filed : November 30, 1999
 For : ISOLATED NUCLEIC ACID MOLECULES ENCODING
 CANCER ASSOCIATED ANTIGENS, THE ANTIGENS
 PER SE, AND USES THEREOF
 Group Art Unit : 1643
 Examiner : Not Assigned

March 2, 2000

Hon. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

LETTER RE SEQUENCES


In response to the January 4 Notice regarding sequence requirements, applicants ask that the attached paper copy of sequence information and CRF of same be made of record.

The undersigned hereby declares that, to the best of his knowledge, the information submitted on the attached paper copy and CRF are identical to each other and to the information presented in the above application as filed. No new matter is presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By



Norman D. Hanson
 Reg. No. 30,946

666 Fifth Avenue
 New York, New York 10103
 (212) 318-3000



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO./TITLE

09/451,739 11/30/99 JAGER

LIT-5615

0222/0104

FULBRIGHT & JAWORSKI LLP
666 FIFTH AVENUE
NEW YORK NY 10103



1643

DATE MAILED:

01/04/00

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. OTHER: _____

APPLICANT MUST PROVIDE:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."

An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.


A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

For Rules Interpretation, call (703) 308-1123.

For CRF submission help, call (703) 308-4212.

For Patentin software help, call (703) 308-6856.


Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE